VaxGen Opens South San Francisco Facility
Brisbane, Calif.-based VaxGen has opened an $11-million facility in South San Francisco that will manufacture the company’s anthrax vaccine, AIDS vaccine, and products ranging from smallpox vaccine to monoclonal antibodies. The 17,000-sf facility is adjacent to the company’s research and development operations, and features stainless steel bioprocessors and purifiers. The facility can be easily reconfigured as manufacturing requirements change as much of the equipment is on wheels.